Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Mar 21, 2023
Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)
Mar 8, 2023
Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level
Photos
1
Jan 18, 2023
Health Canada accepts nirsevimab regulatory submission for infant RSV
Oct 26, 2022
Canadians Encouraged to Live "In Range" to Better Manage their Diabetes
Jun 22, 2022
Sanofi to Launch Artificial Intelligence Centre of Excellence in Toronto
Jun 16, 2022
Sanofi Canada awards second annual Sanofi Biogenius Canada Grants, supporting access to hands-on STEM learning for Canadian students
Jun 15, 2022
Sanofi Canada announces winners of 2022 Sanofi Biogenius Canada Competition
Jun 14, 2022
Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon
May 10, 2022
Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair
May 3, 2022
Sanofi achieves the third year of Gold-level Gender Parity Certification
Mar 28, 2022
Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Mar 25, 2022
Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
Jan 25, 2022
Sanofi Canada named one of Forbes Canada's Best Employers for 2022
Dec 9, 2021
Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin
Nov 15, 2021
Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)
Nov 10, 2021
Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic car
Oct 29, 2021
Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients
Oct 29, 2021
Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations
Oct 13, 2021
New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma
Jul 22, 2021
DUPIXENT® (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
Jul 2, 2021
Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes
Jun 28, 2021
New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin
Jun 17, 2021
DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
Jun 10, 2021
Sanofi Canada awards first annual Biogenius Grants, strengthening equity in STEM learning for Canadian students
Jun 1, 2021
Quebec extends public reimbursement of DUPIXENT® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis to include adolescents
May 25, 2021
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis
Mar 31, 2021
Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine
Mar 22, 2021
Sanofi Canada earns Gold-level gender parity certification for the second straight year
Feb 23, 2021
Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
Jan 28, 2021
Sanofi Canada launches Biogenius Grant for high schools, strengthening commitment to equity in the field of STEM learning
Jan 26, 2021
Sanofi Canada named to Forbes Canada's Best Employers list for 2021
Dec 18, 2020
Health Canada approves expanded indication for SOLIQUA®
Dec 8, 2020
Canadians living with multiple sclerosis find support during COVID-19 pandemic through dedicated social media network
Nov 17, 2020
DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma
Sep 22, 2020
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Aug 18, 2020
DUPIXENT® (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis
Jul 15, 2020
Sanofi Canada increases access to financial assistance for diabetes medications
Jul 14, 2020
DUPIXENT® (dupilumab) receives positive recommendation from INESSS for the treatment of moderate-to-severe atopic dermatitis in adolescents
Jul 8, 2020
SARCLISA™ (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
Jun 17, 2020
Sanofi: Important Information on Plaquenil® and COVID-19
Apr 24, 2020
DUPIXENT® (dupilumab) receives positive recommendation from CADTH for moderate-to-severe atopic dermatitis
Apr 14, 2020
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Apr 2, 2020
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 2, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Jan 30, 2020
Sanofi Canada named a Top Employer in Montreal for 2020, the third similar recognition in the last six months
Nov 22, 2019
Sanofi Canada named one of Canada's Top 100 Employers for 2020
Oct 22, 2019
Patients in Quebec now have access to DUPIXENT™ for the treatment of moderate-to-severe atopic dermatitis
Oct 18, 2019
Sanofi to conduct precautionary voluntary recall of Zantac OTC in Canada and the U.S.
Photos
1
Oct 1, 2019
"Pillars of Strength" photo exhibit opens to celebrate National Seniors Day with compelling images of Canadian Seniors
Sep 27, 2019
Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
Show
5
10
25
50
100
per page
«
1
2
»
